Molecular Metabolism最新文献

筛选
英文 中文
Functional primary human 3D skeletal muscle models enable exercise and metabolic research. 功能初级人体3D骨骼肌模型使运动和代谢研究成为可能。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-11-14 DOI: 10.1016/j.molmet.2026.102474
Simon I Dreher, Robin Schöler, Katharina S Zorn, Jens Martin, Jana Kühnle, Kevin Elsner, Imme Behle, Thomas Goj, Lara Ruoff, Kolja Leffek, Alessia Moruzzi, Peter Loskill, Andre Tomalka, Tobias Siebert, Andreas L Birkenfeld, Andreas Peter, Cora Weigert
{"title":"Functional primary human 3D skeletal muscle models enable exercise and metabolic research.","authors":"Simon I Dreher, Robin Schöler, Katharina S Zorn, Jens Martin, Jana Kühnle, Kevin Elsner, Imme Behle, Thomas Goj, Lara Ruoff, Kolja Leffek, Alessia Moruzzi, Peter Loskill, Andre Tomalka, Tobias Siebert, Andreas L Birkenfeld, Andreas Peter, Cora Weigert","doi":"10.1016/j.molmet.2026.102474","DOIUrl":"https://doi.org/10.1016/j.molmet.2026.102474","url":null,"abstract":"<p><p>Human skeletal muscle is the principal site of insulin-stimulated glucose disposal and a major mediator of exercise-induced metabolic benefits, yet human models that preserve metabolic and exercise responsiveness remain limited. We generated primary human skeletal muscle organoids from donor-derived CD56+ myoblasts using a collagen-based extracellular matrix and serum-free IGF1-guided differentiation. The organoids formed aligned contractile tissues containing oxidative and glycolytic fiber type-like myotubes, displayed enhanced mitochondrial respiration, insulin-stimulated glucose uptake, and reproducible force generation. Electrical pulse stimulation induced AMPK activation, increased glucose utilization and lactate production, and upregulated canonical exercise-responsive genes including NR4A3 and PPARGC1A. Notably, transcriptional responses to in vitro exercise overlapped with acute exercise responses observed in skeletal muscle biopsies from the same donors. The organoids further detected functional impairments of skeletal muscle performance induced by TGF-β1 and metformin and increased speed generation by testosterone treatment. These findings establish a donor-derived human skeletal muscle platform that recapitulates key features of insulin action and exercise adaptation and may enable mechanistic studies of skeletal muscle metabolism, exercise responsiveness, and therapeutic interventions relevant to diabetes.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102474"},"PeriodicalIF":6.3,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large tumor suppressor kinases regulate brown adipocyte thermogenic function and systemic energy homeostasis. 大肿瘤抑制激酶调节棕色脂肪细胞产热功能和全身能量稳态。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-11-11 DOI: 10.1016/j.molmet.2026.102471
Alzbeta Jancovicova, Livia Ban Petriskova, Zuzana Kovanicova, Silvia Zarnovicanova, Roman Urminsky, Adhideb Ghosh, Falko Noe, Alexandra Kellenberger, Tongtong Wang, Natalia Palesova, Patrik Stefanicka, Lukas Varga, Miroslav Tedla, Daniela Nechojdomova, Matej Babinec, Maria Makovicka, Peter Makovicky, Wenfei Sun, Martin Valachovic, Carla Horvath, Anand Kumar Sharma, Lucia Balazova, Christian Wolfrum, Miroslav Balaz
{"title":"Large tumor suppressor kinases regulate brown adipocyte thermogenic function and systemic energy homeostasis.","authors":"Alzbeta Jancovicova, Livia Ban Petriskova, Zuzana Kovanicova, Silvia Zarnovicanova, Roman Urminsky, Adhideb Ghosh, Falko Noe, Alexandra Kellenberger, Tongtong Wang, Natalia Palesova, Patrik Stefanicka, Lukas Varga, Miroslav Tedla, Daniela Nechojdomova, Matej Babinec, Maria Makovicka, Peter Makovicky, Wenfei Sun, Martin Valachovic, Carla Horvath, Anand Kumar Sharma, Lucia Balazova, Christian Wolfrum, Miroslav Balaz","doi":"10.1016/j.molmet.2026.102471","DOIUrl":"https://doi.org/10.1016/j.molmet.2026.102471","url":null,"abstract":"<p><p>Brown and beige adipocytes promote metabolic health by increasing energy expenditure via adaptive non-shivering thermogenesis, yet the molecular mechanisms governing their thermogenic function remain incompletely understood. Here, we identify the Large Tumor Suppressor (LATS) kinases, core components of the Hippo signaling pathway, as important regulators of brown adipocyte thermogenic activity and systemic energy homeostasis. We demonstrate that LATS kinases, particularly LATS2, control thermogenic gene expression, Uncoupling protein 1 (UCP1) levels, and mitochondrial respiration in cultured human and murine brown adipocytes. Mechanistically, loss of LATS kinase activity stabilizes and promotes the nuclear accumulation of the transcriptional co-regulators Yes-associated protein 1 (YAP1) and WW domain-containing transcription regulator 1 (TAZ). We further show that TAZ interacts with Peroxisome proliferator-activated receptor gamma (PPARγ) in murine brown adipocytes. In addition, Lats2 and combined Lats1&2 depletion reduce PPARγ protein abundance and PPARγ binding to a PPAR response element, providing a potential mechanism by which loss of LATS signaling might impair the thermogenic program. Consistent with these findings, brown- and beige-adipocyte-specific deletion of Lats1 and Lats2 in mice reduces UCP1 protein levels in brown adipose tissue and decreases whole-body energy expenditure during cold exposure and β3-adrenergic stimulation with CL-316,243. Despite impaired thermogenic responses, Lats1&2 deficiency in Ucp1-expressing cells protects against diet-induced obesity. The mechanism underlying this protection remains unresolved. Together, these findings identify LATS signaling as an important regulator of thermogenic adipocyte function and implicate the established LATS-YAP1/TAZ-PPARγ regulatory axis in the control of brown adipocyte thermogenesis, while revealing an unexpected association between LATS signaling in thermogenic adipose tissue and systemic energy balance.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102471"},"PeriodicalIF":6.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid mediated ER stress contributes to the pathogenesis of mitochondrial myopathies. 脂质介导的内质网应激有助于线粒体肌病的发病机制。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-11-11 DOI: 10.1016/j.molmet.2026.102472
Inaya Laubach, Guido Primiano, Nneka Southwell, Nicola Rizzardi, Belem Yoval-Sánchez, Christian Bergamini, Serenella Servidei, Alexander Galkin, Giovanni Manfredi, Qiuying Chen, Marilena D'Aurelio
{"title":"Lipid mediated ER stress contributes to the pathogenesis of mitochondrial myopathies.","authors":"Inaya Laubach, Guido Primiano, Nneka Southwell, Nicola Rizzardi, Belem Yoval-Sánchez, Christian Bergamini, Serenella Servidei, Alexander Galkin, Giovanni Manfredi, Qiuying Chen, Marilena D'Aurelio","doi":"10.1016/j.molmet.2026.102472","DOIUrl":"https://doi.org/10.1016/j.molmet.2026.102472","url":null,"abstract":"<p><p>Mitochondrial diseases are a heterogeneous group of genetic disorders caused by impaired oxidative phosphorylation (OxPhos). When skeletal muscle is predominantly affected, they are defined as primary mitochondrial myopathies. Although the genetic causes of mitochondrial myopathies and the resulting bioenergetic impairments are well established, the metabolic drivers behind progressive muscle dysfunction remain poorly defined. This gap in knowledge may contribute to the lack of effective treatments for these disorders. OxPhos defective muscle initiates a metabolic response coordinated by systemic signals which results in muscle and adipose tissue wasting. Here, we show ectopic muscle lipid accumulation in a COX10 KO mouse model of mitochondrial myopathy due to inability to oxidize fatty acids in muscle. In both the mouse model and in mitochondrial patients, we find an increase in ceramides, which is mechanistically linked to chronic ER stress, phosphorylation of eIF2α, and activation of ATF4 signaling. We propose that Ph-eIF2α-mediated attenuation of global protein synthesis and ATF4-initiated atrophy pathways contribute to muscle wasting and weakness. Importantly, inhibition of de novo synthesis of ceramides with myriocin reduces ER stress and ATF4 signaling and improves muscle proteostasis, body weight, and motor functions in the COX10 KO mouse. Together, these findings highlight the role of lipid metabolism as a contributor to mitochondrial myopathy and identify lipid-mediated stress pathways that can be targeted therapeutically.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102472"},"PeriodicalIF":6.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roles for leptin receptor transcriptional targets in the control of body weight. 瘦素受体转录靶点在体重控制中的作用。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-11-06 DOI: 10.1016/j.molmet.2026.102469
Cagri Bodur, Sandra Attisha, Allison Duensing, Abigail Tomlinson, Tammy M Barnes, John G Santinga, Aryan Patel, Martin G Myers
{"title":"Roles for leptin receptor transcriptional targets in the control of body weight.","authors":"Cagri Bodur, Sandra Attisha, Allison Duensing, Abigail Tomlinson, Tammy M Barnes, John G Santinga, Aryan Patel, Martin G Myers","doi":"10.1016/j.molmet.2026.102469","DOIUrl":"10.1016/j.molmet.2026.102469","url":null,"abstract":"<p><p>The adipose-derived hormone leptin activates the signaling isoform of the leptin receptor (LepRb) on hypothalamic neurons to indicate the repletion of energy stores, thereby restraining food intake and body weight. LepRb is a type 1 cytokine receptor whose activation of the transcription factor, STAT3, plays a crucial role in the restraint of food intake and body weight. Hence, the transcriptional targets of LepRb must contribute importantly to leptin action. Our previous analysis of gene expression in hypothalamic Lepr neurons identified several genes that are enriched and consistently leptin-regulated in these cells, including Irf9, Asb4, and Serpina3n. To define potential roles for these genes in the control of energy balance, we deleted them in Lepr neurons (using Lepr<sup>Cre</sup>) or across the hypothalamus (using Nkx2.1<sup>Cre</sup>). Ablating Irf9 or Serpina3n failed to alter body weight or adiposity. In contrast, deleting Asb4 in Lepr neurons increased food intake, body weight, and adiposity, with a tendency toward a larger effect in females. Furthermore, ablating Asb4 throughout the hypothalamus augmented this phenotype. Hence, while Irf9 and Serpina3n in Lepr neurons are dispensable for the control of energy balance, Asb4 expression in Lepr neurons plays a role in the regulation of body weight. Because the loss of Asb4 throughout the hypothalamus further increases obesity, this gene must play Lepr neuron-independent as well as leptin-mediated roles in energy balance.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102469"},"PeriodicalIF":6.3,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery, optimization, and phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist. 一种新型口服GLP-1R/GIPR双重激动剂的发现、优化和一期评估。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-11-03 DOI: 10.1016/j.molmet.2026.102470
Stephanie A Mowery, Patrick J Knerr, Karina Rahr Hjøllund, Birgitte Nissen, Anette K Olsen, Trine Levring Wilkens, Lasse Hjort Kyneb Jakobsen, Christian Hollesen, Kateryna Breusova, Joyce Sorrell, Diego Perez-Tilve, Brian Finan, Richard D DiMarchi, Charlotta Dornonville de la Cour
{"title":"Discovery, optimization, and phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist.","authors":"Stephanie A Mowery, Patrick J Knerr, Karina Rahr Hjøllund, Birgitte Nissen, Anette K Olsen, Trine Levring Wilkens, Lasse Hjort Kyneb Jakobsen, Christian Hollesen, Kateryna Breusova, Joyce Sorrell, Diego Perez-Tilve, Brian Finan, Richard D DiMarchi, Charlotta Dornonville de la Cour","doi":"10.1016/j.molmet.2026.102470","DOIUrl":"10.1016/j.molmet.2026.102470","url":null,"abstract":"<p><strong>Objectives: </strong>The efficacy and convenience of anti-diabetic and anti-obesity therapeutics have surged in recent years due to the emergence of incretin-based poly-pharmacological approaches as well as advances in the oral delivery of peptide drugs. We sought to combine both strategies in an orally deliverable dual agonist of the GLP-1 and GIP receptors.</p><p><strong>Methodology: </strong>We designed a panel of unimolecular, fatty-acylated peptide dual agonists, which was screened for receptor potencies in cell-based assay systems. NNC0130 was selected to advance into clinical studies using both oral and subcutaneous administration.</p><p><strong>Results: </strong>NNC0130 exhibited in vitro potency comparable to semaglutide at human GLP-1R and to tirzepatide at human GIPR, with a chemical structure compatible with semi-recombinant production. Its human half-life of 76-89 h was deemed suitable for once-daily oral administration. In a multiple-ascending dose trial in participants with overweight or obesity and with separate subcutaneous and oral cohorts, daily subcutaneous administration of NNC0130 escalating from 0.3 to 3.0 mg per dose provided a placebo-corrected mean body weight loss of 9% after 12 weeks of treatment and 12% after 15 weeks. Daily oral administration escalating from 5 to 50 mg per dose provided a placebo-corrected mean body weight loss of 4% after 12 weeks, which was not statistically significantly different from zero. The relative oral bioavailability when co-formulated with permeation enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate was estimated to 1.6-2.2% versus s. c. administration.</p><p><strong>Conclusions: </strong>The modest weight-lowering efficacy of orally administered NNC0130 highlights the continued challenges of low oral bioavailability of acylated peptides. However, the substantial efficacy observed with subcutaneous administration motivated advancement into Phase 2 clinical development.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102470"},"PeriodicalIF":6.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism. 谷氨酸能神经元中GIPR的丧失不会损害glp -1通过GIPR拮抗诱导的体重减轻的加速。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-10-31 DOI: 10.1016/j.molmet.2026.102467
Russell L Castelino, Ahmed Khalil, Gandhari Maity-Kumar, Shiqi Zhang, Ophelia Le Thuc, Aaron Novikoff, Daniela Liskiewicz, Robert Gutgesell, Xue Liu, Callum Coupland, Ezgi Karaoglu, Gerald Grandl, Susanna M Hofmann, Alberto Cebrian-Serrano, Stephanie A Mowery, Richard D diMarchi, Jonathan D Douros, Patrick J Knerr, Arkadiusz Liskiewicz, Timo D Müller
{"title":"Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.","authors":"Russell L Castelino, Ahmed Khalil, Gandhari Maity-Kumar, Shiqi Zhang, Ophelia Le Thuc, Aaron Novikoff, Daniela Liskiewicz, Robert Gutgesell, Xue Liu, Callum Coupland, Ezgi Karaoglu, Gerald Grandl, Susanna M Hofmann, Alberto Cebrian-Serrano, Stephanie A Mowery, Richard D diMarchi, Jonathan D Douros, Patrick J Knerr, Arkadiusz Liskiewicz, Timo D Müller","doi":"10.1016/j.molmet.2026.102467","DOIUrl":"10.1016/j.molmet.2026.102467","url":null,"abstract":"<p><strong>Objectives: </strong>Agonism and antagonism of the glucose-dependent insulinotropic polypeptide receptor (GIPR) accelerate weight loss induced by glucagon-like peptide-1 receptor (GLP-1R) agonism. Recent studies have shown that GIPR antagonism, unlike GIPR agonism, does not rely on GIPR signaling in GABAergic neurons to enhance GLP-1-induced weight loss, suggesting that this effect instead depends on GIPR signal modification in other types of neurons. Accordingly, we here assessed whether selective loss of Gipr in glutamatergic neurons affects the ability of GIPR antagonism to enhance GLP-1-induced weight loss.</p><p><strong>Methods: </strong>Mice with deletion of Gipr in excitatory (Vglut2-expressing) glutamatergic neurons were metabolically characterized for alterations in diet-induced obesity (DIO), glucose control and the ability of GIPR antagonism to enhance GLP-1-induced weight loss.</p><p><strong>Results: </strong>Mice lacking GIPR in Vglut2-expressing neurons show improved glucose tolerance despite normal development of diet-induced obesity and remain fully responsive to accelerate GLP-1-induced weight loss by GIPR antagonism.</p><p><strong>Conclusions: </strong>Our results show that GIPR antagonism does not require GIPR signaling in Vglut2-expressing neurons to potentiate GLP-1-induced weight loss, suggesting that the GIPR expressing cells/neurons mediating this effect are neither GABAergic nor Vglut2-expressing glutamatergic.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102467"},"PeriodicalIF":6.3,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity. 差异化肥胖治疗:CRF2的药理激动作用驱动临床前肥胖的脂肪减少、骨骼肌肥大和葡萄糖代谢改善。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-10-31 DOI: 10.1016/j.molmet.2026.102468
Kristoffer Niss, Sofia Lundh, Rucha Patel, Johannes Josef Fels, Albrecht Gruhler, Suzi Høgh Madsen, Fabrice Chimienti, Sarah Bau, Dennis Åsberg, Lennart Lykke, Nick Cox, Birgitte S Wulff, Nikolaj Kulahin Roed, Chien Li, Berit Ø Christoffersen
{"title":"Differentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity.","authors":"Kristoffer Niss, Sofia Lundh, Rucha Patel, Johannes Josef Fels, Albrecht Gruhler, Suzi Høgh Madsen, Fabrice Chimienti, Sarah Bau, Dennis Åsberg, Lennart Lykke, Nick Cox, Birgitte S Wulff, Nikolaj Kulahin Roed, Chien Li, Berit Ø Christoffersen","doi":"10.1016/j.molmet.2026.102468","DOIUrl":"10.1016/j.molmet.2026.102468","url":null,"abstract":"<p><strong>Objective: </strong>Loss of lean mass during weight reduction may compromise metabolic health and physical function. Urocortin 2 (UCN2) activates corticotropin-releasing factor receptor 2 (CRF2) and has been linked to beneficial effects on skeletal muscle and glucose metabolism. We evaluated an acylated UCN2 analogue (acyUCN2), alone or combined with an acylated GLP-1 analogue (acyGLP-1), in preclinical obesity models.</p><p><strong>Methods: </strong>Diet-induced obese (DIO) Sprague Dawley rats and DIO Göttingen Minipigs were treated with vehicle or acyUCN2 (rats, pigs) or acyGLP-1 or combination therapy (rats only). Food intake, body weight (BW), body composition, glucose tolerance and energy expenditure (rats only) were assessed. Histology and RNA-sequencing were used to characterize muscle remodelling and transcriptional responses.</p><p><strong>Results: </strong>In rats, acyUCN2 reduced food intake and fat mass, increased lean mass and muscle weight, and improved glucose tolerance despite limited effects on BW. Energy expenditure was not affected. Histology demonstrated hypertrophy across fibre types and a shift from type 2A to type 2X/B fibres. Transcriptomic analyses supported muscle growth and fibre type switch, relative reduced vasculature, regulation of neuromuscular junction-associated genes, and overlap to human acute exercise-response signatures. In obese minipigs, acyUCN2 increased lean mass and improved insulin sensitivity, with modest effects on BW and fat mass, alongside regulation of genes linked to muscle biology and metabolism.</p><p><strong>Conclusions: </strong>Pharmacological CRF2 agonism promotes favourable body composition, muscle hypertrophy, and improved glucose metabolism despite limited weight loss, supporting clinical development of UCN2 analogues as a differentiated obesity treatment, particularly in combination with appetite-regulating therapies and in settings where preservation of functional muscle mass is critical.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102468"},"PeriodicalIF":6.3,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy targeting an endogenous retrovirus decreases islet senescence markers and preserves glucose control in a mouse model of type 2 diabetes. 在2型糖尿病小鼠模型中,针对内源性逆转录病毒的免疫治疗可降低胰岛衰老标志物并保持葡萄糖控制。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-10-29 DOI: 10.1016/j.molmet.2026.102466
Daniel Bjørklund Andersen, Nanna Skeltved, Gabriel Mira González, Thomas Garde-Due, Iker Ausina, Clara Iacumin, Lasse Neukirch, Anne-Marie Andersson, Emeline Ragonnaud, Joachim Størling, Claus Desler, Frederik Otzen Bagger, Kaare Villum Grunddal, Peter Johannes Holst
{"title":"Immunotherapy targeting an endogenous retrovirus decreases islet senescence markers and preserves glucose control in a mouse model of type 2 diabetes.","authors":"Daniel Bjørklund Andersen, Nanna Skeltved, Gabriel Mira González, Thomas Garde-Due, Iker Ausina, Clara Iacumin, Lasse Neukirch, Anne-Marie Andersson, Emeline Ragonnaud, Joachim Størling, Claus Desler, Frederik Otzen Bagger, Kaare Villum Grunddal, Peter Johannes Holst","doi":"10.1016/j.molmet.2026.102466","DOIUrl":"10.1016/j.molmet.2026.102466","url":null,"abstract":"<p><p>Type 2 diabetes is characterized by progressive metabolic stress and accumulation of senescent cells in key metabolic tissues, such as the pancreas, adipose tissue, and liver. Cellular senescence - an irreversible growth-arrested, and pro-inflammatory cell state can lead to induction of endogenous retrovirus (ERV) expression, which can also trigger cellular senescence. This possibly implies that a self-reinforcing ERV-senescence axis contributes to the metabolic decline and T2D. Here we developed and tested a mouse endogenous retrovirus (muERV) based active immunotherapy targeted at the most intact muERV, IAPE (Intracisternal A-type Particles elements with an Envelope) to eliminate cells expressing muERVs and senescence-associated proteins in a mouse model of accelerated diabetes combining a high-fat diet (HFD) with dexamethasone (DEX) and streptozotocin (STZ) (DS-HFD). Immunized DS-HFD mice (DS-HFD + IAPE-Tx) showed increased B and T cell responses towards IAPE. Antisera generated using our IAPE-targeted active immunotherapy was used to confirm activation of IAPE expression in the murine β-cell line MIN-6, following both inflammatory (cytokines) and chemical stress (STZ and DEX). In vivo, DS-HFD + IAPE-Tx mice showed reduced weight gain, improved fasting insulin-glucose homeostasis and oral glucose tolerance. They furthermore showed reduction in histomorphometry features consistent with steatosis, hepatocyte binucleation, reduced adipocyte size, and pancreatic islet senescence markers p16<sup>INK4a</sup> and p21<sup>Cip1/waf1</sup>, with a slight decrease in islet IAPE. Finally, we show activation of a human orthologue to IAPE, HERV-K, in cytokine-exposed isolated human pancreatic islets and EndoC-βH5 β-cells. Together, our results suggest that ERV antigens are expressed in metabolic disease models and may be targeted by immunotherapy to improve metabolic parameters, through a potential senolytic or senostatic-related but so far undefined mechanism.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102466"},"PeriodicalIF":6.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. 持续的CagriSema治疗通过减少大鼠的能量摄入和维持能量消耗来保持体重减轻。
IF 6.3 2区 医学
Molecular Metabolism Pub Date : 2026-10-28 DOI: 10.1016/j.molmet.2026.102464
Lisbeth M Petersen, Filip K Knop, Carel W le Roux, Kirsten Raun, Marc L Reitman, Rune E Kuhre
{"title":"Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.","authors":"Lisbeth M Petersen, Filip K Knop, Carel W le Roux, Kirsten Raun, Marc L Reitman, Rune E Kuhre","doi":"10.1016/j.molmet.2026.102464","DOIUrl":"10.1016/j.molmet.2026.102464","url":null,"abstract":"<p><strong>Purpose: </strong>CagriSema (CS), combining the amylin receptor agonist cagrilintide with the glucagon-like peptide 1 receptor agonist semaglutide, is being developed for obesity and type 2 diabetes. We quantified CS effects on energy balance during initial treatment, weight maintenance, and after discontinuation.</p><p><strong>Methods: </strong>Male diet-induced obese rats underwent indirect calorimetry during 6 weeks of treatment and for 4 weeks after discontinuation. Treatments were a) vehicle, b) CS, c) calorie-restriction to match CS body weight loss (weight matched, WM), and d) calorie-restriction to match CS food intake (pair-feeding, PF).</p><p><strong>Results: </strong>CS effects occurred in four phases. During days 1-10 (Phase I), CS induced rapid weight loss mainly through reduced energy intake (EI), while energy expenditure (EE) was relatively preserved. EE was significantly lower in WM rats, consistent with metabolic adaptation. During days 11-42 (Phase II), reduced body weight was maintained in the CS, WM, and PF groups, and respiratory exchange ratio converged across groups, indicating metabolic steady state had been reached. Reduced EI and preserved total EE respectively explained 86% and 14% of CS weight loss efficacy. Maintained resting/sleeping EE contributed to the total EE preservation. Treatment discontinuation (days 43-52, Phase III) caused hyperphagia and rapid weight regain. During days 53-68 (Phase IV), all groups reached metabolic steady state and weight gain returned to pretreatment rates. Body weight plateaued in approximately half the time needed to reach metabolic steady state, and metabolic adaptation reversed within ∼7 days after discontinuation.</p><p><strong>Conclusions: </strong>By persistently lowering EI and attenuating metabolic adaptation, CS enables sustained weight loss in rats; however, the reversal after treatment cessation suggests that chronic pharmacological therapy may be required to maintain weight loss.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102464"},"PeriodicalIF":6.3,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations 利用GLP-1受体c端突变模拟G蛋白偏向性激动作用。
IF 6.6 2区 医学
Molecular Metabolism Pub Date : 2026-03-01 Epub Date: 2026-01-20 DOI: 10.1016/j.molmet.2026.102321
Hanh Duyen Tran , Yiming Zuo , Carissa Wong , Alice Pollard , Steve Bloom , Ben Jones
{"title":"Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations","authors":"Hanh Duyen Tran ,&nbsp;Yiming Zuo ,&nbsp;Carissa Wong ,&nbsp;Alice Pollard ,&nbsp;Steve Bloom ,&nbsp;Ben Jones","doi":"10.1016/j.molmet.2026.102321","DOIUrl":"10.1016/j.molmet.2026.102321","url":null,"abstract":"<div><h3>Background and aim</h3><div>The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for type 2 diabetes and obesity. Agonists showing bias in favour of G protein signalling over β-arrestin recruitment and GLP-1R internalisation, e.g. tirzepatide and orforglipron, have favourable clinical efficacy profiles. However, understanding of the effects of biased agonism has been hampered by differences in ligand properties such as affinity, efficacy, stability and pharmacokinetics. Here we used GLP-1R C-tail mutations that inhibit phosphorylation to mimic G protein-biased GLP-1R agonism without the need for ligand modifications.</div></div><div><h3>Methods</h3><div>Serine doublet phosphorylation sites in the human and mouse GLP-1R C-tails were mutated to alanine. Wild-type and mutant GLP-1Rs were examined for β-arrestin recruitment, internalisation, Gα<sub>s</sub> activation, and signalling readouts in HEK293 cells and pancreatic β-cell models. Native GLP-1 plus oppositely biased ligands exendin-phe1 (ExF1; G protein-biased) and exendin-asp3 (ExD3; β-arrestin-biased) were used to compare ligand- and receptor-mediated biased agonism.</div></div><div><h3>Results</h3><div>Loss of three C-terminal phosphorylation sites reduced GLP-1- and ExD3-mediated GLP-1R internalisation and β-arrestin recruitment to that seen with ExF1. The phosphodeficient GLP-1R showed preferential plasma membrane Gα<sub>s</sub> activation over longer stimulations, with associated increases in whole cell cAMP generation and kinomic signalling. The distal GLP-1R phosphorylation site played a larger role in β-arrestin recruitment, and the proximal sites were more important for GLP-1R internalisation and regulating cAMP production.</div></div><div><h3>Conclusions</h3><div>Genetic changes that reduce β-arrestin recruitment and slow GLP-1R internalisation can enhance GLP-1R signalling, providing conceptual support for the use of G protein bias to improve GLP-1R agonist efficacy.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"105 ","pages":"Article 102321"},"PeriodicalIF":6.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书